Akarna Therapeutics Ltd.
http://www.akarna.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Akarna Therapeutics Ltd.
Allergan’s Two-Year NASH Data Fail To Show Fibrosis Benefit
A year after acquiring cenicriviroc in its Tobira buyout, Allergan says two-year data from a Phase IIb trial supports continued development, but analysts think the drug’s prospects have dimmed.
M&A Analysis Reveals Mid Pharma Purchase Preferences
Immunology- and inflammation-focused biotech companies wondering if a trade exit is in their future will be interested to read that, according to a report from Datamonitor Healthcare, their demographic is the most popular acquisition target of the mid-size pharma cohort.
J&J Innovation’s Latest Deal Spree Includes CB-1 Antibody For NASH
Option to acquire a company developing a CB1-targeted antibody for non-alcoholic steatohepatitis gets Johnson & Johnson into the race. Janssen’s James List explains how the NASH venture fits into J&J’s growing efforts in metabolic disease.
Top M&A Of 2016: Cast Your Vote!
It's time once again for In Vivo's Deal of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice